All - Everyone posting concerns about ENTs not treating them with FX-322 needs to stop applying the current reality to a future state where the drug exists in the market.
If FX-322 continues to show positive outcomes for hearing loss in the clinical trials, the knowledge of it by ENTs will improve through media awareness, professional training/education, and patient awareness. Not to mention, this drug will be a cash cow for Frequency and the drug maker in the US. There will be commercials for it to raise awareness (see: Ocrevus, etc), considering the market is so substantial.
Some drug makers are so interested in getting the drug in you, they make websites available to point you to the doctors that can provide treatment. FX-322 will be no exception.